Profitelligence Profitelligence · Filing Ledger Open JNJ research →

Form 8-K · Current Report · Filed 2024-09-20

Johnson & Johnson's Subsidiary Files for Chapter 11 Bankruptcy to Resolve Talc Litigation

On September 20, 2024, Johnson & Johnson's subsidiary, Red River Talc LLC, filed for a voluntary prepackaged Chapter 11 bankruptcy to resolve all current and future claims related to ovarian cancer arising from cosmetic talc litigation.

Filer
Johnson & Johnson JNJ · NYSE
Filed
Accession
0000200406-24-000083
CIK
0000200406
Signal
Low impactHealthcare

Details

The bankruptcy plan, supported by approximately 83% of current claimants and the Future Claims Representative, proposes a settlement of approximately $8 billion. The Company has increased its contribution to the settlement by $1.75 billion.

Items reported

Item 7.01

Regulation FD Disclosure

Regulation FD Disclosure
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$164.82

Next session

-1.0%

Since filing

+55.5%

Latest close

$256.35

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from JNJ reporting the same item, with the next session's move:

Exhibits (1)

About Johnson & Johnson

Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another JNJ filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts